Porton J-STAR announced that Enabling Technologies Consortium (ETC) has awarded a two-year contract to J-STAR to collaborate on "Co-processing Platform Technology." The primary goal of co-processing is to improve the reliability and efficiency of drug product manufacturing processes to support direct compression or continuous manufacturing techniques. Co-processed APIs offer solutions to challenges like inadequate powder flow, low bulk density, broad particle size distribution, and compressibility, facilitating direct compression. When traditional methods such as API crystallization through solvent selection, supersaturation control, seeding, or milling techniques are insufficient, co-processing of API with excipients can significantly improve the functional properties to overcome these challenges.

ETC members sought to establish a collaboration with a third party to develop co-processing platform technology to leverage this technique to avoid these API crystallization challenges. In order to select their collaborator, ETC had a public call requesting proposals for a co-processing technology platform solution. Following an extensive and rigorous evaluation of numerous proposals submitted by industry service providers and academic institutions, ETC selected Porton J-STAR to deliver commercial co-processing platform technology to the industry and scientific community.

Under the terms of the Development Contract, ETC member companies will collaborate with Porton J-STAR to develop the Co-processing Technology Platform.